Cell-based molecularly targeted therapy: targeting oncoproteins with T cell receptor gene therapy
نویسندگان
چکیده
منابع مشابه
Targeting human melanoma neoantigens by T cell receptor gene therapy.
In successful cancer immunotherapy, T cell responses appear to be directed toward neoantigens created by somatic mutations; however, direct evidence that neoantigen-specific T cells cause regression of established cancer is lacking. Here, we generated T cells expressing a mutation-specific transgenic T cell receptor (TCR) to target different immunogenic mutations in cyclin-dependent kinase 4 (C...
متن کاملCAR T-cell Therapy of Hematologic Malignancies: An Update in Targeted Antigens
Immunotherapy with genetically engineered T-cells that express the chimeric antigen receptor (CAR) has raised hopes for the treatment of pediatric malignancies. Although CAR T-cell development is on a fast-moving pace and evolution, the context of exploring novel targetable antigens has been neglected. In this review study, we analyze the prominent hematologic antigens targeted by engineered T-...
متن کاملStem Cell-Based Therapy (Cell Therapy) in Iran and other Countries
Cell therapy is a modern approach in the treatment of most of the diseases which uses stem cells and it has been recently developed rapidly. Cell therapy has shown satisfactory results in this way. Our country, Iran, has played an important role in the development of this new method and the results of stem cell treatment used for the most of the diseases were successful. The results have led to...
متن کاملCell targeting in anti-cancer gene therapy.
Gene therapy is a promising approach towards cancer treatment. The main aim of the therapy is to destroy cancer cells, usually by apoptotic mechanisms, and preserving others. However, its application has been hindered by many factors including poor cellular uptake, non-specific cell targeting and undesirable interferences with other genes or gene products. A variety of strategies exist to impro...
متن کاملOptimizing T-cell receptor gene therapy for hematologic malignancies.
Recent advances in genetic engineering have enabled the delivery of clinical trials using patient T cells redirected to recognize tumor-associated antigens. The most dramatic results have been seen with T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19, a differentiation antigen expressed in B cells and B lineage malignancies. We propose that antigen expression i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Investigation
سال: 2018
ISSN: 0021-9738,1558-8238
DOI: 10.1172/jci120386